Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643609 | 0.78 | CYP3A4 (0.52) | SIGMAR1CYP3A4OPRM1OPRD1OPRK1 | |
| SCHEMBL7168539 | 0.78 | CYP3A4 (0.44) | SIGMAR1CYP3A4OPRM1OPRD1OPRK1 | |
| SCHEMBL1513248 | 0.75 | SLC6A2 (0.42) | SIGMAR1KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1513240 | 0.74 | SLC6A2 (0.44) | SIGMAR1KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4984411 | 0.73 | POLA1 (0.51) | SIGMAR1KDM1ACYP3A4 | |
| SCHEMBL29587519 | 0.73 | POLA1 (0.51) | SIGMAR1KDM1ACYP3A4 | |
| SCHEMBL8865370 | 0.73 | OPRM1 (0.49) | SIGMAR1KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7321561 | 0.72 | SIGMAR1 (0.51) | SIGMAR1KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1143677 | 0.72 | CYP3A4 (0.46) | SIGMAR1KDM1ACYP3A4OPRM1OPRD1 | |
| SCHEMBL9252967 | 0.71 | KDM1A (0.50) | SIGMAR1KDM1ASLC6A2SLC6A4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | SIGMAR1 4393/4885KDM1A 3120/4885SLC6A2 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.